Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | HTR7 | P34969 | 9/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24322614 | 1.00 | KDM4E (0.45) | KDM4EHTR7GAASMN1; SMN2HRH3 | |
| SCHEMBL24322383 | 1.00 | KDM4E (0.45) | KDM4EHTR7GAASMN1; SMN2HRH3 | |
| SCHEMBL24322393 | 1.00 | KDM4E (0.45) | KDM4EHTR7GAASMN1; SMN2HRH3 | |
| SCHEMBL12449634 | 0.82 | KDM4E (0.50) | KDM4EHTR7HRH3ALDH1A1LMNA | |
| SCHEMBL13995508 | 0.82 | KDM4E (0.50) | KDM4EHTR7HRH3ALDH1A1LMNA | |
| SCHEMBL13077 | 0.82 | KDM4E (0.50) | KDM4EHTR7HRH3ALDH1A1LMNA | |
| SCHEMBL8557026 | 0.80 | CARM1 (0.55) | HTR7HRH3 | |
| SCHEMBL8557028 | 0.80 | CARM1 (0.55) | HTR7HRH3 | |
| SCHEMBL9274604 | 0.79 | CARM1 (0.48) | HRH3MAPT | |
| SCHEMBL8594059 | 0.77 | CARM1 (0.46) | HRH3ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | KDM4E 4426/4885HTR7 49/4885GAA 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.